Work

392-P: Phase 1, Randomized, Controlled Trial of GFB-024, a Once-Monthly CB1 Inverse Agonist, in Healthy Overweight and Obese Participants and in Participants with Type 2 Diabetes Mellitus

Year: 2022

Type: article

Study design: Clinical Trial

Source: Diabetes

DOI: 10.2337/db22-392-p

Authors: GREGORY GAICH, SANELA BILIC, YOSSI DAGON, THOMAS GUSTAFSON, JOHN LAWLER, LESLIE JOHNSON, LORI RUDOLPH-OWEN

Language: English

Topic: Cannabis and Cannabinoid Research

Subfield: Pharmacology (medical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281665347

FWCI: 0.289

Cites:

Cited by: 2

Related to: 10